Inhibikase Therapeutics, Inc. (IKT) stock
IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.38−0.07 (-4.83%)
Close on Nov 17, 2026Market cap $192.56MP/E –Yield –
Inhibikase Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Inhibikase Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $38.24M, up 40.8% year over year. For fiscal 2025 it was $29.79M, up 73.1% from the year before. The highest annual figure on record is $29.79M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.79M | +73.1% |
| FY2024 | Dec 31, 2024 | $17.21M | +26.4% |
| FY2023 | Dec 31, 2023 | $13.62M | +13.2% |
| FY2022 | Dec 31, 2022 | $12.03M | +6.0% |
| FY2021 | Dec 31, 2021 | $11.36M | +1170.9% |
| FY2020 | Dec 31, 2020 | $893.80K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $13.39M | +154.1% |
| Q1 FY2026 | Mar 31, 2026 | $10.84M | +3.1% |
| Q4 FY2025 | Dec 31, 2025 | $6.36M | -11.6% |
| Q3 FY2025 | Sep 30, 2025 | $7.65M | +82.6% |
| Q2 FY2025 | Jun 30, 2025 | $5.27M | +71.4% |
| Q1 FY2025 | Mar 31, 2025 | $10.51M | +282.1% |
| Q4 FY2024 | Dec 31, 2024 | $7.19M | +139.5% |
| Q3 FY2024 | Sep 30, 2024 | $4.19M | +29.9% |
| Q2 FY2024 | Jun 30, 2024 | $3.08M | -32.2% |
| Q1 FY2024 | Mar 31, 2024 | $2.75M | -3.6% |
| Q4 FY2023 | Dec 31, 2023 | $3.00M | -1.7% |
| Q3 FY2023 | Sep 30, 2023 | $3.23M | +8.2% |
| Q2 FY2023 | Jun 30, 2023 | $4.54M | +52.1% |
| Q1 FY2023 | Mar 31, 2023 | $2.85M | -5.4% |
| Q4 FY2022 | Dec 31, 2022 | $3.05M | +28.2% |
| Q3 FY2022 | Sep 30, 2022 | $2.98M | +22.6% |
| Q2 FY2022 | Jun 30, 2022 | $2.98M | +1214.1% |
| Q1 FY2022 | Mar 31, 2022 | $3.02M | +2402.3% |
| Q2 FY2021 | Jun 30, 2021 | $2.38M | +805.3% |
| Q1 FY2021 | Mar 31, 2021 | $2.43M | +759.0% |
| Q4 FY2020 | Dec 31, 2020 | $226.94K | – |
| Q3 FY2020 | Sep 30, 2020 | $120.57K | – |
| Q2 FY2020 | Jun 30, 2020 | $263.18K | – |
| Q1 FY2020 | Mar 31, 2020 | $283.11K | – |
See a number that looks wrong?